Description
An agonist of PPARα (EC50 = 0.9 µM in a transactivation assay); selective for PPARα over PPARγ and PPARδ at 300 µM; induces cell cycle arrest at the G2/M and S phases in Fao, but not HepG2, cells at 250 µM; decreases fasting plasma levels of triglycerides and increases fasting plasma glucose levels in the apolipoprotein CIII transgenic mouse model of hypertriglyceridemia at 10 mg/kg